New Treatments Uses T-Cells to Fight Cancer at the "Root"

Dear [fname],

One of the major road blocks in cancer research has been the unchecked mutations undergone by cancer cells, creating a moving target. An international team recently made a discovery that could overcome the problem, leading to a breakthrough for integrative immunotherapy methods.

Targeting the "tree trunk"

The group of researchers found that, in addition to random mutations, cancer cells within an individual also share specific mutations that can be isolated and attacked. Dr. Sergio Quezada of University College London's Cancer Institute, co-author of the study, likened the approach to killing a "tree trunk" rather than fighting a tangle of branches.

Creating customized treatment

Dr. Quezeda went on to explain that a customized vaccine could be developed to attack the core mutations in a particular patient. Another possibility would be discovering which T-cells produced by the immune system fight the specific mutations. Those T-cells would then be "fished" from the patient, multiplied in a lab, and re-injected into the body.

What's in the future?

According to Dr. Quezeda, he believes these specialized treatments would be most effective against melanoma and lung cancer. Both are on the list of the 10 most common forms of cancer in the United States. Dr. Quezeda is hopeful that, in light of this study, trials will begin within five years.

Issels targets the "root" cause

Our Issels® integrative immunotherapy centers have long been in the forefront of using personalized treatment protocols. Each patient receives a specifically created program based on genetic predisposition, lifestyle, environment and other individual factors.

Visit our website to read and watch testimonials from patients who have been successfully treated at the Issels® Treatment Centers.

Read more interesting articles on the "Issels Integrative Immuno-Oncology" news/blog posted every Tuesday and Thursday. Check It Out Now »

Targeted Cell Therapy May Lead to the End of Chemotherapy

Immunotherapy is changing the cancer treatment landscape. Advancements in targeted cell therapy may make chemotherapy obsolete within our lifetime. The biggest problem with traditional cancer treatments – chemotherapy, radiation and surgery – is that they destroy healthy tissue along with diseased cancerous tissue. By shifting the battle field from the tissue level to the cellular level, targeted cell therapy aims to destroy only cancerous cells, leaving healthy cells whole and untouched.

For the first time, researchers have discovered that the enzyme PKR is activated during cellular mitosis. PKR was previously known as a trigger of immune response during a viral infection. It is believed that the disruption of PKR activation causes a delay in mitotic progression and defects in cell division that ultimately results in cancer growth.